Despite its promising results in animal models, mTOR inhibition by rapamycin and its derivatives, called rapalogs, was much less effective in patients, may elicit severe side effects ([251], reviewed in [252]) and offer only temporary improvements which is unsuitable to the therapy of a chronic disease such as ADPKD. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.